<DOC>
	<DOCNO>NCT00101088</DOCNO>
	<brief_summary>This phase I trial study side effect best dose temsirolimus give imatinib mesylate treat patient chronic myelogenous leukemia . Drugs use chemotherapy , temsirolimus , work different way stop growth cancer cell , either kill cell stop dividing . Imatinib mesylate may stop growth cancer cell block enzymes need cell growth . Giving temsirolimus imatinib mesylate may kill cancer cell</brief_summary>
	<brief_title>Temsirolimus Imatinib Mesylate Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety tolerability temsirolimus administer imatinib mesylate patient chronic myelogenous leukemia . II . Determine potential dose-limiting toxic effect regimen patient . III . Determine , preliminarily , hematologic cytogenetic response rate patient treated regimen . OUTLINE : This multicenter , dose-escalation study temsirolimus . Patients receive temsirolimus intravenously ( IV ) 30 minute day 1 , 8 , 15 , 22 oral imatinib mesylate daily day 1-28 . Courses repeat every 28 day absence unacceptable toxicity disease progression . Patients receive 2 additional course beyond maximal response . Cohorts 3-6 patient receive escalate dos temsirolimus maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow survival .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologically confirm chronic myelogenous leukemia ( CML ) Philadelphia chromosomepositive OR BcrAblpositive disease , meet 1 follow criterion : Accelerated phase , define least 1 follow : 1019 % blast peripheral blood bone marrow At least 20 % basophils peripheral blood bone marrow Platelet count &lt; 100,000/mm^3 ( unrelated therapy ) Platelet count &gt; 1,000,000/mm^3 ( unresponsive therapy ) Increasing splenomegaly AND increase WBC count ( unresponsive therapy ) Clonal evolution Blast phase , define 1 following : At least 20 % blast peripheral blood bone marrow Extramedullary disease Chronic phase , define follow : Less 10 % blast peripheral blood bone marrow Less 20 % basophils peripheral blood bone marrow Platelet count &gt; 100,000/mm^3 Absence clonal evolution May receive and/or failed prior imatinib mesylate therapy Patients previously treat imatinib mesylate receive oral imatinib mesylate daily 14 day begin study drug Must able tolerate 600 mg per day imatinib mesylate start CCI779 Patients chronic phase disease must fail prior imatinib mesylate dose ≥ 600 mg/day , define 1 following : Must achieve must lose hematologic response within 3 month start imatinib mesylate Must achieve must lose cytogenetic response 6 month treatment imatinib mesylate Must achieve must lose major cytogenetic response 12 month treatment imatinib mesylate Must lose complete cytogenetic response Bone marrow aspirate biopsy cytogenetics fluorescent situ hybridization confirming ( 9 ; 22 ) complete within past 28 day Performance status SWOG 02 More 3 month See Disease Characteristics Bilirubin normal AST ALT &lt; 2.5 time upper limit normal ( ULN ) ( 5 time ULN suspect liver involvement leukemia ) Creatinine normal Creatinine clearance &gt; 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Ejection fraction ≥ 50 % echocardiogram MUGA scan patient know positive cardiac history ( e.g. , heart failure , coronary artery disease , cardiomegaly prior chest xray , valvular heart disease ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Fasting cholesterol ≤ 350 mg/dL Fasting triglycerides ≤ 400 mg/dL No history allergic reaction attribute compound similar chemical biologic composition temsirolimus imatinib mesylate No active ongoing infection No psychiatric illness social situation would preclude study compliance No active malignancy except nonmelanoma skin cancer No uncontrolled illness At least 48 hour since prior interferon alfa CML At least 6 week since prior stem cell transplantation No concurrent biologic agents No concurrent prophylactic colonystimulating factor At least 24 hour since prior hydroxyurea CML At least 7 day since prior mercaptopurine vinca alkaloid CML At least 7 day since prior lowdose cytarabine ( &lt; 30 mg/m^2 every 1224 hour ) CML At least 14 day since prior homoharringtonine CML At least 14 day since prior moderatedose cytarabine ( 100200 mg/m^2 57 day ) CML At least 21 day since prior anthracyclines , mitoxantrone , cyclophosphamide , etoposide , methotrexate CML At least 28 day since prior highdose cytarabine ( 13 g/m^2 every 1224 hour 612 dos ) CML At least 6 week since prior busulfan CML No concurrent hydroxyurea No concurrent chemotherapy At least 7 day since prior steroid CML No prior organ transplantation More 2 week since prior major surgery ( e.g. , thoracotomy intraabdominal surgery ) Recovered prior therapy Prior experimental therapy allow provided completion treatment correspond duration &gt; 5 halflives experimental drug know active metabolite study No concurrent cyclosporine No concurrent anagrelide No concurrent oral anticoagulant , include warfarin No concurrent CYP3A4 inducer inhibitors No concurrent tacrolimus No concurrent plasmapheresis No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>